Stewart Abbot has been appointed chief scientific officer of Adicet Bio. Before coming to the Menlo Park, CA-based company, Abbot was chief development officer at Fate Therapeutics (NASDAQ: [[ticker:FATE]]) in La Jolla, CA. Adicet launched in 2016 backed by a $51 million Series A round of financing to develop “off-the-shelf” immune cell therapies for cancer and other diseases.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
